A Study to Describe the Safety and Immunogenicity of a RSV Vaccine in Healthy Adults
A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER-BLIND, DOSE-FINDING, FIRST-IN-HUMAN STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN HEALTHY ADULTS
Sponsor: Pfizer
This PHASE2 trial investigates Respiratory Tract Infections and is currently completed. Pfizer leads this study, which shows 14 recorded versions since 2018 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE2
-
Jun 2021 — Apr 2022 [monthly]
Completed PHASE2
▶ Show 9 earlier versions
-
Apr 2021 — Jun 2021 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2021 — Apr 2021 [monthly]
Active Not Recruiting PHASE2
-
Sep 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE2
-
Jun 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2
-
Mar 2020 — Jun 2020 [monthly]
Active Not Recruiting PHASE2
-
Nov 2019 — Mar 2020 [monthly]
Active Not Recruiting PHASE2
-
Sep 2019 — Nov 2019 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Jul 2018 — Sep 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE2
First recorded
Apr 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .